Sagimet Biosciences (SGMT) Accounts Payables (2022 - 2026)

Sagimet Biosciences' Accounts Payables history runs 5 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 28.54% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 28.54% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 8.14% from the prior year.
• Accounts Payables rose to $2.3 million in Q1 2026 per SGMT's latest filing, from $1.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.2 million in Q3 2025 and bottomed at $186000.0 in Q4 2023.
• The 5-year median for Accounts Payables is $1.7 million (2023), against an average of $1.8 million.
• Across the five-year window, Accounts Payables tumbled 83.47% in 2023 and jumped 666.13% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $1.1 million in 2022, then tumbled by 83.47% to $186000.0 in 2023, then soared by 666.13% to $1.4 million in 2024, then slipped by 8.14% to $1.3 million in 2025, then soared by 75.94% to $2.3 million in 2026.
• Per Business Quant, the three latest SGMT Accounts Payables figures stand at $2.3 million (Q1 2026), $1.3 million (Q4 2025), and $4.2 million (Q3 2025).